Micardisplus (Hydrochlorothiazide, Telmisartan)

• Micardisplus is used to treat hypertension, a condition characterized by elevated arterial pressure, by targeting the renin‑angiotensin system and promoting diuresis.
• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Essential hypertension: provides sustained blood pressure control when monotherapy is insufficient.
• Secondary hypertension: assists in achieving target pressures in patients with underlying causes such as renal disease.

• Telmisartan selectively blocks AT1 receptors for angiotensin II, preventing vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits Na+/Cl‑ reabsorption in the distal convoluted tubule, increasing urinary sodium and water excretion. The combined actions reduce peripheral vascular resistance and plasma volume, resulting in lowered blood pressure.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue or weakness
• Increased frequency of urination
• Electrolyte disturbances such as low potassium
• Mild gastrointestinal discomfort

Serious or Rare Side Effects

• Severe allergic reactions (rash, swelling, anaphylaxis)
• Acute kidney injury or worsening renal function
• Hyperkalemia, especially when combined with potassium‑sparing agents
• Significant drops in blood pressure (hypotension)
• Pancreatitis or severe abdominal pain

Before initiating therapy, clinicians should assess renal function, electrolyte status, and blood pressure response.

• Monitor blood pressure regularly: adjust therapy based on readings.
• Check renal function and serum electrolytes: especially potassium and sodium.
• Use caution in patients with hepatic impairment: dose adjustments may be needed.
• Elderly patients may be more susceptible to hypotension and electrolyte shifts.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Micardisplus may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Aliskiren (in diabetic patients): increased risk of renal impairment and hyperkalemia.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.
• ACE inhibitors or other ARBs: combined use can lead to excessive potassium rise and renal dysfunction.

Moderate Interactions (Monitor Closely)

• NSAIDs (e.g., ibuprofen, naproxen): may blunt antihypertensive effect and affect kidney function.
• Lithium: increased lithium levels, risk of toxicity.
• Rifampin or other CYP inducers: may reduce telmisartan plasma concentrations.